Filing Flows › Rhythm Pharmaceuticals (RYTM) › R&D spending
Rhythm Pharmaceuticals (RYTM) R&D spending by quarter
Rhythm Pharmaceuticals' R&D spending was $52.5M in Q3 2026 (third quarter 2026), +21% from Q2 2026. Over the last 7 quarters it ranged from $37.0M (Q1 2025) to $52.5M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $52.5M | +21% | +14% |
| Q2 2026 | $43.4M | +4% | +3% |
| Q1 2026 | $41.7M | -0.7% | +13% |
| Q4 2025 | $42.0M | -9% | — |
| Q3 2025 | $46.0M | +9% | — |
| Q2 2025 | $42.3M | +14% | — |
| Q1 2025 | $37.0M | — | — |
Q3 2026 at a glance
Rhythm Pharmaceuticals, Q3 2026: revenue $92.1M (+80% year over year), operating margin -42.6%, net loss $41.4M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Rhythm Pharmaceuticals' R&D spending?
Rhythm Pharmaceuticals' R&D spending was $52.5M in Q3 2026 (third quarter 2026), +21% from Q2 2026.
How has Rhythm Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $37.0M (Q1 2025) to $52.5M (Q3 2026).
Q3 2026 results → · How Rhythm Pharmaceuticals makes money →